Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Empasiprubart by Argenx for Delayed Graft Function (DGF): Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Delayed Graft Function (DGF). According to GlobalData,...
Empasiprubart by Argenx for Dermatomyositis: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs...
Empasiprubart by Argenx for Multifocal Motor Neuropathy: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Multifocal Motor Neuropathy. According to GlobalData, Phase...
Empasiprubart by Argenx for Dermatomyositis: Likelihood of Approval
Empasiprubart is under clinical development by Argenx and currently in Phase II for Dermatomyositis. According to GlobalData, Phase II drugs...
Risk adjusted net present value: What is the current valuation of Argenx's Empasiprubart?
Empasiprubart is a monoclonal antibody commercialized by Argenx, with a leading Phase II program in Multifocal Motor Neuropathy. According to...
Risk adjusted net present value: What is the current valuation of Argenx's Empasiprubart?
Empasiprubart is a monoclonal antibody commercialized by Argenx, with a leading Phase II program in Multifocal Motor Neuropathy. According to...